Martek Biosciences — Merger or Acquisition (January 2010)
15 slides from Martek Biosciences's merger presentation, Jan 21, 2010
Slide 1: Martek Biosciences Acquisition of Amerifit Brands
Martek Biosciences Acquisition of Amerifit Brands January 21, 2010
Slide 2: Forward Looking Statements
Forward Looking Statements Sections of this presentation contain forward-looking statements concerning, among other things, expectations regarding the timing and financial impact of the proposed acquisition, GAAP and pro forma financial information, future revenue growth, product introductions, prod
Slide 3: Strategic Rationale
Strategic Rationale Provides Martek with first class sales and marketing infrastructure and a proven and highly experienced management team for selling branded consumer health and wellness products Moves Martek up the value chain and closer to the consumer Martek is now positioned to capture a large
Slide 4: Discussion Items
Discussion Items Amerifit Acquisition Review Transaction Summary Amerifit Overview Martek Business and Guidance Update Q1 Martek update FY’10 impact of transaction 4
Slide 5: Transaction Summary
Transaction Summary 5 Purchase Price $200 million, subject to working capital closing adjustments Transaction Financing $120 million cash on hand; $80 million borrowed under new credit facility Transaction Details Platform acquisition – branded consumer products Expense synergies are not expected Cl
Slide 6: Amerifit Overview
Amerifit Overview 6 Overview Amerifit develops, markets and distributes branded consumer health and wellness products Founded 1985; acquired by private equity firm Charterhouse in 2005 Employees Seasoned and successful senior management team Experience – Pepsi, Colgate-Palmolive, P&G, Burt’s Bees 65
Slide 7: Amerifit's Major Brands
Amerifit’s Major Brands Source: Nielsen. Market position in “FDMx” channel, as defined by Nielsen (food, drug and mass channels excluding Walmart). As of 11/28/09. Brand Overview Leading all-natural probiotic supplement Only OTC dietary supplement with Lacto-bacillus GG bacterial strain OTC leader i
Slide 8: Pipeline of Potential Branded Products
Pipeline of Potential Branded Products 8 DHA Memory product (MIDAS study) Other Products (cardiovascular health, joint health, others) 2010 2011 2012 2013 Amerifit Products Martek Products Culterelle Estroven AZO Other DHA-related products On the Market Development
Slide 9: Financial Overview
Financial Overview Amerifit Financial Profile 2009 revenue of approximately $81 million 2009 gross margins approximately 70% 2009 estimated adjusted EBITDA* of approximately $22 million Transaction Metrics Purchase price of approximately 9.0x 2009 Adjusted EBIDTA and 8.0x – 8.3x forecasted 2010 EBIT
Slide 10: Amerifit Historical Revenue and Adjusted EBITDA
Amerifit Historical Revenue and Adjusted EBITDA 10 Note: Amerifit financials are presented on a calendar year basis in contrast to Martek’s fiscal year which ends 10/31. * See Table 1 of Appendix “Amerifit Financial Addendum” for a reconciliation of this non-GAAP measure to comparable GAAP measure.
Slide 11: Martek Q1'10 Guidance Update
Martek Q1’10 Guidance Update Prior Q1 Guidance Updated Q1 Guidance Total Revenue $85m - $89m $88m - $90m Infant Formula Revenue $67m - $71m $70m - $71.5m Non-IF Revenue $10m - $11m $11m - $11.5m Gross Margin 43.5% - 44.5% 43.5% - 44.5% Non-GAAP EPS prior to acquisition expenses $0.29 - $0.32 $0.30 -
Slide 12: Preliminary Forecasted Impact of Acquisition to Martek
Preliminary Forecasted Impact of Acquisition to Martek 12 $ in millions, except EPS Projected Additions to Martek’s FY’10 a Amerifit Projected Full Year Pro Forma d Amerifit Projected Actual b Amerifit Projected Pro Forma c Revenue $61m - $63m $61m - $63m $89m - $91m Gross margin $41.5m - $43.5m $42
Slide 13: Summary
Summary Provides Martek with first class sales and marketing infrastructure and proven and highly experienced management team for selling branded consumer health and wellness products Moves Martek up the value chain and closer to the consumer Serves as a platform for controlling and accelerating the
Slide 14: Appendix: Reconciliations
APPENDIX Reconciliations CONFIDENTIAL
Slide 15: Amerifit Financial Addendum
Amerifit Financial Addendum ($ in millions) Pro Forma 8 mos. Ending 12 month 10/31/2010 results Projected net income $3.0 - $4.0 $8.0 - $9.0 Projected transaction expenses, net of tax 1.0 1.0 Projected one-time purchase accounting inventory write-up/COGS charge, net of tax 0.5 0.5 Projected Non-GAAP
Martek Biosciences — Merger or Acquisition (January 2010) on 6ix